Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (1 active)

Company-led only

5 results

Therapy	Approach	Progress	Population	Additional Info
PEDMARK by Fennec PharmaceuticalsFennec Pharmaceuticals Compare	Small Molecule	Stage: MarketedStatus: Marketed	Children · ≥1 month (pediatric indication)Localized, non-metastatic tumors receiving cisplatin
SENS-401 (Arazasetron) by SensorionSensorion Compare	Small Molecule	Stage: Phase 2Status: Active	Adults · ≥18 yearsSSNHL, cisplatin, or cochlear-implant cohorts
SPI-1005 by Sound PharmaceuticalsSound Pharmaceuticals Compare	Small Molecule	Stage: Phase 3Status: Active	Adults · 18–75 yearsActive Ménière’s disease
ACOU085 by Acousia TherapeuticsAcousia Therapeutics GmbH Compare	Small Molecule	Stage: Phase 2Status: Active	Adults · 18–45 yearsTesticular cancer receiving high-dose cisplatin
DB-020 by Regeneron and DecibelRegeneron Pharmaceuticals Compare	Drug Delivery	Stage: Phase 1Status: Completed	Adults · ≥18 yearsCancer patients receiving high-dose cisplatin

PEDMARK by Fennec Pharmaceuticals

Fennec Pharmaceuticals · Small Molecule · Marketed

MarketedTherapeuticStronger sources

Population

Children · ≥1 month (pediatric indication)

Localized, non-metastatic tumors receiving cisplatin

Evidence

regulatory

Confidence

98%

Indications

Cisplatin-Induced Hearing LossHearing Loss

SENS-401 (Arazasetron) by Sensorion

Sensorion · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Population

Adults · ≥18 years

SSNHL, cisplatin, or cochlear-implant cohorts

Evidence

company

Confidence

94%

Indications

Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCisplatin-Induced Hearing Loss

SPI-1005 by Sound Pharmaceuticals

Sound Pharmaceuticals · Small Molecule · Phase 3

ActiveTherapeuticStronger sources

Population

Adults · 18–75 years

Active Ménière’s disease

Evidence

trial

Confidence

90%

Indications

Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus

ACOU085 by Acousia Therapeutics

Acousia Therapeutics GmbH · Small Molecule · Phase 2

ActiveTherapeuticStronger sources

Population

Adults · 18–45 years

Testicular cancer receiving high-dose cisplatin

Evidence

company

Confidence

93%

Indications

Hearing LossSensorineural Hearing LossAge-Related Hearing LossCisplatin-Induced Hearing Loss

DB-020 by Regeneron and Decibel

Regeneron Pharmaceuticals · Drug Delivery · Phase 1

CompletedTherapeutic

Population

Adults · ≥18 years

Cancer patients receiving high-dose cisplatin

Evidence

publication

Confidence

92%

Indications

Cisplatin-Induced Hearing LossHearing Loss

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked